share_log

Avenue Therapeutics | S-3: Registration statement for specified transactions by certain issuers

Avenue Therapeutics | S-3: Registration statement for specified transactions by certain issuers

Avenue Therapeutics | S-3:特定交易注册声明
美股sec公告 ·  05/06 12:47
Moomoo AI 已提取核心信息
Avenue Therapeutics, Inc. (Avenue), a specialty pharmaceutical company, has filed a Form S-3 with the Securities and Exchange Commission (SEC) on May 3, 2024. The filing pertains to the registration of 1,420,741 shares of common stock underlying certain common warrants and placement agent warrants. These warrants were issued in connection with a private placement transaction that closed on May 1, 2024. The Series C and Series D Warrants, exercisable at $6.20 per share, and the Placement Agent Warrants, exercisable at $7.75 per share, are part of the registration. The Series C and Placement Agent Warrants are exercisable immediately and for a period of five years from the date of issuance, while the Series D Warrants are exercisable for eighteen months from issuance. The Selling Stockholders may sell...Show More
Avenue Therapeutics, Inc. (Avenue), a specialty pharmaceutical company, has filed a Form S-3 with the Securities and Exchange Commission (SEC) on May 3, 2024. The filing pertains to the registration of 1,420,741 shares of common stock underlying certain common warrants and placement agent warrants. These warrants were issued in connection with a private placement transaction that closed on May 1, 2024. The Series C and Series D Warrants, exercisable at $6.20 per share, and the Placement Agent Warrants, exercisable at $7.75 per share, are part of the registration. The Series C and Placement Agent Warrants are exercisable immediately and for a period of five years from the date of issuance, while the Series D Warrants are exercisable for eighteen months from issuance. The Selling Stockholders may sell the shares at any time after the effective date of the Registration Statement, through various methods including but not limited to brokerage transactions, block trades, and private sales. Avenue will not receive any proceeds from the sale of the shares by the Selling Stockholders but will receive proceeds from any cash exercise of the warrants. The common stock is listed on The Nasdaq Capital Market under the symbol 'ATXI'.
专业制药公司Avenue Therapeutics, Inc.(Avenue)已于2024年5月3日向美国证券交易委员会(SEC)提交了S-3表格。该文件涉及某些普通认股权证和配售代理认股权证所依据的1,420,741股普通股的注册。这些认股权证的发行与2024年5月1日完成的私募交易有关。C系列和D系列认股权证(可按每股6.20美元行使)和配售代理认股权证(每股7.75美元)是注册的一部分。C系列和配售代理认股权证可立即行使,自发行之日起五年内行使,而D系列认股权证自发行之日起十八个月内可行使。卖出股东可以在注册声明生效之日后的任何时候通过各种方法出售股票,包括但不限于经纪交易、大宗交易和私人销售。Avenue不会从出售股东出售股票中获得任何收益,但将从认股权证的任何现金行使中获得收益。普通股在纳斯达克资本市场上市,股票代码为 “ATXI”。
专业制药公司Avenue Therapeutics, Inc.(Avenue)已于2024年5月3日向美国证券交易委员会(SEC)提交了S-3表格。该文件涉及某些普通认股权证和配售代理认股权证所依据的1,420,741股普通股的注册。这些认股权证的发行与2024年5月1日完成的私募交易有关。C系列和D系列认股权证(可按每股6.20美元行使)和配售代理认股权证(每股7.75美元)是注册的一部分。C系列和配售代理认股权证可立即行使,自发行之日起五年内行使,而D系列认股权证自发行之日起十八个月内可行使。卖出股东可以在注册声明生效之日后的任何时候通过各种方法出售股票,包括但不限于经纪交易、大宗交易和私人销售。Avenue不会从出售股东出售股票中获得任何收益,但将从认股权证的任何现金行使中获得收益。普通股在纳斯达克资本市场上市,股票代码为 “ATXI”。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息